[1] Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. Eur Heart J 2016; 37: 353−364. doi: 10.1093/eurheartj/ehv712 [2] Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J 2017; 58: 475−480. doi: 10.1536/ihj.17-191 [3] Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155−2166. doi: 10.1056/NEJMoa1409312 [4] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016; 134: e123–e155. [5] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541−2619. doi: 10.1093/eurheartj/ehu278 [6] Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association; Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians; Editorial Board of Chinese Journal of Cardiology. [Chinese guideline for percutaneous coronary intervention (2016)]. Zhonghua Xin Xue Guan Bing Za Zhi 2016; 44: 382−400. [In Chinese]. doi: 10.3760/cma.j.issn.0253-3758.2016.05.006 [7] Xu J, Song Y, Gao Z, et al. Long-term outcomes of extending dual antiplatelet therapy after drug-eluting stent implantation for acute coronary syndrome: a large single-center study. Platelets 2020; 31: 869−876. doi: 10.1080/09537104.2019.1693036 [8] Chinese Elderly Type 2 Diabetes Prevention and Treatment of Clinical Guidelines Writing Group; Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Society; Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Health Care Society; Geriatric Professional Committee of Beijing Medical Award Foundation; National Clinical Medical Research Center for Geriatric Diseases (PLA General Hospital). [Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]. Zhonghua Nei Ke Za Zhi 2022; 61: 12−50. [In Chinese]. doi: 10.3760/cma.j.cn112138-20211027-00751 [9] Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289−1367. doi: 10.1093/eurheartj/ehaa575 [10] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581−1598. doi: 10.1016/j.jacc.2012.08.001 [11] Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736−2747. doi: 10.1161/CIRCULATIONAHA.110.009449 [12] Patsouras A, Farmaki P, Garmpi A, et al. Screening and risk assessment of coronary artery disease in patients with type 2 diabetes: an updated review. In Vivo 2019; 33: 1039−1049. doi: 10.21873/invivo.11572 [13] [14] Pultar J, Wadowski PP, Panzer S, et al. Oral antiplatelet agents in cardiovascular disease. Vasa 2019; 48: 291−302. doi: 10.1024/0301-1526/a000753 [15] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016; 134: e123–e155. [16] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213−260. doi: 10.1093/eurheartj/ehx419 [17] Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology; Interventional Cardiology Working Group of Chinese Society of Cardiology; Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians; Specialty Committee on Coronary Artery Disease and Atherosclerosis of Chinese College of Cardiovascular Physicians; Editorial Board of Chinese Journal of Cardiology. [Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi 2021; 49: 432−454. [In Chinese]. doi: 10.3760/cma.j.cn112148-20210125-00088 [18] Bonaca MP, Murphy SA, Miller D, et al. Patterns of long-term thienopyridine therapy and outcomes in patients withacute coronary syndrome treated with coronary stenting: observations from the TIMI-38 Coronary Stent Registry. Clin Cardiol 2014; 37: 293−299. doi: 10.1002/clc.22247 [19] Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119: 149−162. doi: 10.1055/s-0038-1676545 [20] Xu JJ, Gao Z, Zhang Y, et al. Dual antiplatelet therapy after coronary drug-eluting stent implantation in China: a large single center study. Catheter Cardiovasc Interv 2018; 91: 566−572. doi: 10.1002/ccd.27500